| Ytd | -72.71% | |
| 1y | -81.26% |
| Open | 2.43 | Prev Close | 2.40 | Low | 2.42 | High | 2.49 | Mkt Cap | 20.67M |
| Vol | 6.43K | Avg Vol | 154.56K | EPS | -3.42 | P/E | -0.70 | Forward P/E | -3.81 |
| Beta | 1.25 | Short Ratio | 14.73 | Inst. Own | 28.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 3.46 | 200-d Avg | 7.49 | 1yr Est | 6.00 |
ATOS News
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Pote
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDA
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon
US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus
US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, com
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon
Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breas
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and b
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovati
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer e
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company
Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer r
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atoss
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Comp
Hyperfine (NASDAQ: HYPR - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.
Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarker
Shares of Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) have earned a consensus recommendati
Atossa Genetics Inc. (NASDAQ: ATOS - Get Free Report) saw a large growth in short interest during th
SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Co
Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies fo
Atossa Genetics Inc. (NASDAQ: ATOS)'s stock is scheduled to reverse split before the market opens on
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
On Thursday, 241 companies hit new 52-week lows.
Monday saw 825 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
Before 10 a.m. ET Monday, 296 stocks made new 52-week highs.
Thursday's morning session saw 73 companies set new 52-week highs.
Stocks That Hit 52-Week Lows On Wednesday
Stocks Which Set New 52-Week Low Friday, October 26th